STAT+: A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease

Roche reported negative results Thursday from a long-running clinical trial investigating an experimental antibody treatment in people born with an inherited form of early onset Alzheimer’s disease.

The Swiss pharma giant has been running the Phase 3 clinical trial for more than a decade, aiming to show that an antibody called crenezumab that targets toxic brain plaques might slow or even prevent Alzheimer’s disease in people born with a specific genetic mutation that typically causes cognitive impairment to begin around age 44.

Continue to STAT+ to read the full story…